[EN] COMPOSITIONS COMPRISING A METAL SOURCE, DITHIOCARBAMATE AND CYCLODEXTRIN<br/>[FR] COMPOSITIONS COMPRENANT UNE SOURCE MÉTALLIQUE, UN DITHIOCARBAMATE ET UNE CYCLODEXTRINE
申请人:DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
公开号:WO2018069525A1
公开(公告)日:2018-04-19
The present invention provides a novel class of dithiocarbamate-metal complexes and their uses in medicine. Also provided by the invention are combinations and pharmaceutical compositions, comprising a dithiocarbamate (or thiuram disulphide) such as disulfiram and cyclodextrin, with a source of a heavy metal. Surprisingly, the inventors found a synergistic potentiation of the anti-tumor effect, when a dithiocarbamate/heavy metal mixture was combined with a cyclodextrin. The compounds and combination of the invention are particularly useful in the treatment of tumor diseases, and other disorders. Provided are the compounds, combination, pharmaceutical compositions and kits, as well as methods for the preparation of the combinations of the invention.
IMPROVED DITHIOCARMABATE BASED COMPOUNDS, THERAPIES AND DIAGNOSTICS
申请人:Deutsches Krebsforschungszentrum,
Stiftung des öffentlichen Rechts
公开号:EP3693740A1
公开(公告)日:2020-08-12
The present invention provides an improved class of dithiocarbamate complexes with increased tumour spheroid activity. The invention provides the novel compounds as such, and their medical application for the treatment of tumour diseases. The compounds of the invention are surprisingly effective compared to the prior art dithiocarbamates, in particular with respect to tumour spheroids. Another aspect of the herein described invention provides a diagnostic determination of tumours with increased susceptibility to a treatment with the dithiocarbamates of the invention. This aspect of the invention suggests determining components of the thioredoxin 1 (TRX1)/thioredoxin reductase 1 (TRXR1) system as an indicator of treatment responders. In context of this inventive aspect, the dithiocarbamate compounds of the invention were identified as competitive TRXR1 binders, and hence, the TRX1-amount in tumours is an important factor for treatment success.
L'invention concerne une composition immunogène, caractérisée en ce qu'elle comprend une protéine adénylcyclase-hémolysine (AC-Hly) ou une partie immunogène de cette AC-Hly, d'une souche de Bordetella choisie parmi B. pertussis, B. parapertussis ou B. bronchiseptica et en ce qu'elle comprend en outre un extrait bactérien contenant les produits d'expression des gènes vrg d'une souche de Bordetella choisie parmi B. pertussis, B. parapertussis ou B. bronchiseptica ou une partie de ces produits d'expression, suffisante pour induire une réponse immunitaire chez un hôte auquel l'extrait serait administré.
The present invention relates to a composition having improved or enhanced fidelity and/or longevity of the fragrance profile, comprising fragrance materials in a diamond construction and at least one substantially non-odorous fragrance modulator. The invention also relates to methods of use of the compositions for perfuming suitable substrates, including hard surfaces and body parts, particularly skin and hair.
COMPOSITIONS COMPRISING DITHIOCARBAMATE AND CYCLODEXTRIN
申请人:Deutsches Krebsforschungszentrum Stiftung des
Öffentlichen Rechts
公开号:EP3311843A1
公开(公告)日:2018-04-25
The present invention provides combinations and pharmaceutical compositions comprising a dithiocarbamate such as disulfiram and cyclodextrin, with a source of a heavy metal. Surprisingly, we found a synergistic potentiation of the anti-tumor effect, when a dithiocarbamate/heavy metal mixture was combined with a cyclodextrin. The combination of the invention is particularly useful in the treatment of tumor diseases, and other disorders. Provided are the combination, pharmaceutical compositions and kits, as well as methods for the preparation of the combinations of the invention.